Comparing Fulcrum Therapeutics (NASDAQ:FULC) & Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals (NASDAQ:SYRS) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, earnings and profitability.

Earnings and Valuation

This table compares Syros Pharmaceuticals and Fulcrum Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syros Pharmaceuticals	$9.94 million	0.47	-$164.57 million	($3.03)	-0.06
Fulcrum Therapeutics	$2.81 million	76.02	-$97.33 million	($0.31)	-12.77

Fulcrum Therapeutics has lower revenue, but higher earnings than Syros Pharmaceuticals. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by insiders. Comparatively, 4.1% of Fulcrum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Syros Pharmaceuticals and Fulcrum Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syros Pharmaceuticals	0	4	1	0	2.20
Fulcrum Therapeutics	1	6	3	0	2.20

Syros Pharmaceuticals currently has a consensus target price of $3.33, indicating a potential upside of 1,802.59%. Fulcrum Therapeutics has a consensus target price of $9.33, indicating a potential upside of 135.69%. Given Syros Pharmaceuticals’ higher possible upside, research analysts plainly believe Syros Pharmaceuticals is more favorable than Fulcrum Therapeutics.

Profitability

This table compares Syros Pharmaceuticals and Fulcrum Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%
Fulcrum Therapeutics	N/A	-7.31%	-6.74%

Volatility & Risk

Syros Pharmaceuticals has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.06, suggesting that its stock price is 106% more volatile than the S&P 500.

Summary

Fulcrum Therapeutics beats Syros Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.